Compare Capri Holdings Ltd (CPRI) vs Heron Therapeutics Inc (HRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Capri Holdings Ltd vs Heron Therapeutics Inc — how do they compare? Capri Holdings Ltd trades at $14.75 (market cap $1.67B), while Heron Therapeutics Inc trades at $0.4 (market cap $68.01M). The key difference: Capri Holdings Ltd is far larger — about 24.6× Heron Therapeutics Inc's market cap, and Capri Holdings Ltd is more actively traded (3,722,279 versus 1,891,941). Which is the better fit depends on your goals — on Pluang, investors hold Capri Holdings Ltd for 41 Days and Heron Therapeutics Inc for 35 Days on average.
| CPRI | HRTX | |
|---|---|---|
Market Cap | $1.67B | $68.01M |
Volume | 3,722,279 | 1,891,941 |
Sector | Consumer Cyclical | Health |
52-Week High | $27.66 | $1.49 |
52-Week Low | $12.71 | $0.27 |
Typical Hold Time | 41 Days | 35 Days |
Enterprise Value | $2.95B | $174.75M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPRI trades at $14.44, down 1.57% today, with a bearish technical outlook despite recent earnings beats. The stock shows mixed signals with strong profitability metrics (62.71% gross margin, 252.89% ROE) but concerning fundamental trends including declining revenue from $5.7B in 2022 to $4.4B in 2025 and a significant net loss of -$1.18B. Recent news highlights management's focus on brand revitalization and second-half growth expectations for Michael Kors and Jimmy Choo brands.
The investment case balances attractive valuation (P/S 0.51) against substantial operational challenges. Analyst consensus leans neutral with a $20.57 price target representing 42% upside, but investors face risks from continued revenue declines, high debt levels, and the ongoing Michael Kors turnaround execution. The stock offers potential value if management's growth initiatives gain traction in the second half of 2026.
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Capri Holdings Ltd
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →
